Loading
NASDAQHealthcareBiotechnology
Latest quote
$5.31
+$0.13 · +2.51%
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Previous close
$5.31
+$0.13 · +2.51%
Regular session · ET · Market data may be delayed.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Day range
Current $5.31
52-week range
Current $5.31
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
25
Expensive
Sentiment
54
Mixed
Risk
40
Moderate Risk
Momentum
58
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Day range
Current $5.31
52-week range
Current $5.31
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 351.37M USD |
| Cost of goods sold | — | 83.37M USD | 70.09M USD | 62.39M USD | 167.21M USD |
| Gross profit | — | −83.37M USD | −70.09M USD | −62.39M USD | 184.16M USD |
| Research and development | 148.02M USD | 145.4M USD | 132.84M USD | 88.84M USD | 167.21M USD |
| Selling, general, and administrative | 32.86M USD | 48.85M USD | 49.92M USD | 48.71M USD | 45.79M USD |
| Operating expenses | 180.89M USD | 109.58M USD | 94.07M USD | 68.26M USD | 45.79M USD |
| Interest income | 16.38M USD | 25.49M USD | 29.22M USD | 11.15M USD | 213K USD |
| Interest expense | — | — | — | 11.15M USD | — |
| Depreciation and amortization | 416K USD | 416K USD | 416K USD | 260K USD | 29K USD |
| Operating income | −180.89M USD | −192.95M USD | −164.16M USD | −130.65M USD | 138.38M USD |
| Net income | −158.35M USD | −168.39M USD | −135.96M USD | −115.91M USD | 121.19M USD |
Company facts updated Sep 14, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$7.00
31.83% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI9.55M0.00%2.3T USD0.03%$376.31+0.82%
iShares Russell 2000 ETFIWM9.33M0.01%78.38B USD0.19%$288.89+0.41%
Vanguard Extended Market ETFVXF4.08M0.00%93.7B USD0.05%$237.76+0.68%
iShares Russell 2000 Value ETFIWN3.5M0.02%14.34B USD0.24%$219.69+0.33%
iShares Biotechnology ETFIBB2.52M0.02%10.34B USD0.44%$202.93+0.14%
Vanguard Russell 2000 ETFVTWO1.87M0.01%17.4B USD0.06%$116.76+0.36%
Schwab U.S. Small-Cap ETFSCHA1.79M0.01%22.43B USD0.03%$33.79+0.42%
Dimensional - US Small Cap ETFDFAS1.37M0.01%15.49B USD0.26%$80.52+0.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHADimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
